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MRD in multiple myeloma: more questions
than answers?
Philippe Moreau1 and Elena Zamagni2
The growing interest in minimal residual disease (MRD)
assessment in multiple myeloma (MM) is related to the
high quality of responses achieved with novel agents and
to the development of reliable techniques to evaluate
MRD both within the bone marrow using next-generation
sequencing (NGS) or next-generation flow cytometry
(NGF), and outside the bone marrow using imaging
techniques, such as positron emission tomography-
computed tomography (PET-CT)1. A consensus paper
by the International Myeloma Working Group (IMWG),
published in 2016, represents the reference document on
MRD in MM2. However, since its publication, new data
have become available, and it is of interest to discuss what
other information beyond that included in the IMWG
criteria should be captured in ongoing clinical trials
(Table 1).
Minimal residual disease certainly matters in MM.
Munshi et al. recently published a meta-analysis on 496
patients in complete response (CR), in whom an MRD-
negative status was associated with a significant
improvement in both progression-free survival (PFS) and
overall survival (OS)3. These findings were recently con-
firmed by the Spanish group in a pooled analysis of three
PETHEMA/GEM clinical trials involving 609 patients,
showing that MRD-negative status surpassed the prog-
nostic value of CR achievement for PFS and OS4. In the
paper by the Spanish group and in the majority of the
trials included in the meta-analysis by Munshi et al. MRD
was mostly assessed by flow cytometry, with a sensivity
level of 10−4 on average. In the IMWG consensus paper,
the definition of MRD negativity requires a minimum
sensitivity of 1 in 105 nucleated cells or higher both for
flow and sequencing technology. The NGS technology,
which is quite well standardized, routinely reaches a
sensitivity level of 10−61. The NGF technology, may easily
reach a sensitivity level of 10−5, if not 10−6, when using
the standardized EuroFlow approach1, 5.
Therefore, an interesting question is whether a higher
level of sensitivity will result in a better predictability, and
whether we should try to routinely increase the depth of
MRD detection to 10−6. In the French IFM 2009 study6,
which compared RVD versus RVD plus autologous
stem cell transplantation (ASCT), MRD was evaluated
both by 7-color flow cytometry in all patients and by NGS
where possible. Minimal residual disease negativity eval-
uated by flow was associated with a PFS and OS benefit
(sensitivity level of 10−4). Of note, among flow-negative
cases, the NGS technology was associated with a higher
sensitivity (10−6) and allowed the segregation of patients
into two groups: flow-negative, NGS-negative and flow-
negative, NGS-positive, with a significantly worse PFS
outcome in the latter population7. These results indicate
that 10−6 might be the ideal cut-off for the definition of
MRD negativity. This is even more plausible when the
number of patients reaching 10−6 in this study was 80 out
of 131 evaluable patients7. A sensitivity threshold is
informative and meaningful when it can be reached by a
significant number of patients in a specific therapeutic
strategy.
The next question is: NGS or NGF? NGS is now stan-
dardized, but the EuroFlow consortium recently described
a novel NGF approach using an optimized 2-tube 8-color
antibody panel for highly sensitive (close to 10−6) and
standardized MRD detection that could be implemented
in routine diagnostic procedures. In a small number of
samples, a comparison of the two techniques showed a
good correlation in the percentage of residual abnormal
plasma cells detected, with a similar sensitivity5. In addi-
tion, the EuroFlow technology was recently evaluated in
the prospective EMN02 trial, which compared ASCT to
bortezomib-based conventional therapy without ASCT
and showed a significant impact of flow negative MRD on
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PFS8. Overall, these data indicate that both techniques
may be used to evaluate MRD, despite some differences in
terms of applicability, availability, cost, sampling, or cell
characterization.
What about the role of imaging for the assessment of
MRD in 2017? New data on the role of PET-CT have
recently been published. In the IFM2009 study6, the
prognostic impact of PET-CT was convincingly demon-
strated9. These data were achieved in the context of a
prospective study using RVD, which is one of the most
effective combinations upfront, and they confirm the
prognostic impact of PET-CT already described by the
Little-Rock10 and Bologna11 groups. Another important
piece of information provided by this study concerns the
complementary role of PET-CT and flow cytometry. A
subgroup of patients was evaluated by both PET-CT and
by 7-color flow cytometry. Overall, the concordance
between the two techniques was low. Progression-free-
survival was significantly higher for the group of patients
with both a normalized PET-CT and negative MRD by
flow versus patients with either PET positivity and/or
MRD positivity. When using a Cox model to analyze the
impact of a normalized PET-CT, negative MRD and their
interaction, the only remaining factor was the interaction,
indicating that these two tools may be complementary in
predicting patient outcome. Indeed, although we strongly
support the use of PET-CT for the evaluation of metabolic
response to therapy, it is important to emphasize that
both false negative and false positive results may be seen.
The Little Rock group recently found that almost 10% of
newly diagnosed MM patients had a false negative PET
imaging at diagnosis12, indicating that new, more sensitive
PET-CT tracers, or other imaging modalities, such as
whole body diffusion weighted magnetic resonance ima-
ging, should be investigated in the future. Moreover,
attempts to standardize FDG PET/CT interpretation cri-
teria are ongoing13.
In addition, other important questions remain unsolved.
One relates to the concept of sustained MRD negativity.
The IWMG consensus paper proposed the confirmation
of NGS/NGF and PET negativity a minimum of one year
apart2. This point is of utmost importance in order to
define rules for stopping treatment (during maintenance
for example), or to introduce the concept of cure, but, as
mentioned by Kumar et al, the definition of sustained
MRD negativity was arbitrarily made2. However, the
number of required monitorings of MRD negativity and
the time interval between them should be defined pro-
spectively. This is also true for the new definition of
relapse in the IMWG manuscript:2 ‘relapse from MRD
negativity, that is loss of MRD-negative status with evi-
dence of clonal plasma cells on NGS or NGF, or positive
imaging study for recurrence of MM’. What exactly is «
loss of MRD-negative status »: a change from 10−6 to
10−5, 10−5 to 10−4? Do we need confirmation on two
consecutive samples or is one increment sufficient to
define relapse? What are the clinical implications of this
finding: resumption of interrupted treatment, change of
therapy, careful observation in case of absence of bio-
chemical or clinical progression? Indeed, the definition of
“loss of MRD-negative status”, which needs clarification,
will also impact the new definition of disease-free survival
Table 1 MRD in multiple myeloma
Validated points Open issues
MRD negativity is a surrogate for PFS Optimal threshold for PFS and/or OS prediction by NGS or NGF
MRD negativity is a surrogate for OS Need for both NGS and NGF
MRD by NGS is standardized Time interval to define sustained MRD negativity
MRD by NGF (Euroflow) is standardized Definition of loss of MRD-negative status
MRD by NGS or NGF and PET-CT are complementary Optimal timing for MRD assessment during and after treatment
MRD useful to compare treatment options Meaning of MRD negativity in specific subgroups, i.e., high-risk cytogenetics
Standardization of MRD by PET-CT
Best tracer for PET-CT
MRD to alter therapy: duration of maintenance, change treatment, add agents…
Blood-based MRD assessment
MRD and detection of clonal evolution
MRD and MGUS-like profile
MRD as a valid end-point for drug approval
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proposed in 2016, which is the duration from the start of
MRD negativity to the time of reappearance of MRD2.
The optimal timing for MRD assessment also remains to
be defined.
Overall, MRD assessment will become key in the follow-
up of patients with MM. Experts are in agreement that
MRD negativity is one of the best prognostic markers, a
surrogate for PFS and OS. It is hoped that ongoing
(Table 2) and future trials will help to define the optimal
use of the technologies to assess MRD, which will
potentially determine and tailor our therapeutic strategies.
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